Work

Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure

Year: 2026
Type: article
Study design: Case Report
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce serum uric acid levels through enhanced urinary excretion; however, individual responses vary. We report the case of a man in his late 60s with heart failure with reduced ejection fraction who experienced a marked reduction in serum uric acid to 3 mg/dL after the initiation of empagliflozin 10 mg daily. This reduction was accompanied by an increase in the fractional excretion of uric acid from 2.89% to 6.59%. Uric acid reduction was sustained during follow-up without clinically relevant adverse events and the patient remained clinically stable. Background urate-lowering therapy remained unchanged before and throughout SGLT2 inhibitor treatment, and no changes were made to concomitant medications during follow-up. SGLT2 inhibitor use may lead to a substantial reduction in serum uric acid levels in select patients and enhanced urinary uric acid excretion may contribute to this effect.
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7225340195
FWCI:
Cites: 8
Cited by:
Related to: 10